Image

Results of the Use of Two Stentrievers Simultaneosly Compared With One as a Primary Treatment in Acute Ischemic Stroke

Results of the Use of Two Stentrievers Simultaneosly Compared With One as a Primary Treatment in Acute Ischemic Stroke

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Several studies have demonstrated that simultaneous treatment with two stentrievers (STs) as rescue treatment is very effective, with high recanalization rates even in this group of patients where other revascularization techniques have failed. There has been no observed increase in hemorrhagic complications. Recently, a prospective study has been published where treatment with two ST has been shown to be effective and safe if used as a first-choice treatment (not as rescue) with a successful recanalization rate (eTICI 2c/3) after the first pass of 69%. These results have been reinforced after the publication of a randomized study that confirms, in vitro, the superiority of using two ST over one.

Description

The use of a double stent retriever has been proposed as a safe and effective technique. The investigators hypothesized that the use of double stentriever primary could lead to higher first pass effect rates and better outcomes compared to single stentriever primary.

Our goal is to develop a research project to provide additional information on the potential benefits of the simultaneous double stent approach primarily in stroke patients receiving endovascular treatment.

A randomized study to compare the efficacy of double primary stentriever versus single primary stentriever.

Eligibility

Inclusion Criteria:

  • A new disabling focal neurological deficit compatible with acute cerebral ischemia.
  • Any age. Informed consent obtained from the patient or representative.
  • NIHSS score ≥ 6.
  • Pre-existing functional clinical status less than or equal to 2 according to the mRS clinical scale.
  • Maximum time of 24 hours from symptom onset to arterial puncture. • TICI 0-1 in the diagnosed TICA (terminal internal carotid artery) , MCA (middle cerebral artery), and BA( basilar artery confirmed by angioCT and angiography).
  • ASPECTs score on baseline CT greater than or equal to 6.
  • In cases where it is indicated, prior intravenous fibrinolysis will be administered according to the protocols of each center.

Exclusion Criteria:

  • Those described in the usual protocols for mechanical thrombectomy of each hospital.
  • Pre-existing functional clinical status greater than 2 according to the mRS clinical scale
  • Patients with tandem lesions of dissection or arteriosclerotic origin located in the extracranial internal carotid artery.
  • Initiation of treatment with a different technique than the one described.
  • Inability to use a proximal balloon guide catheter.
  • Use of aspiration catheter.
  • Intracranial atherosclerotic plaque as the cause of occlusion.
  • Advanced or terminal disease with a life expectancy of less than 6 months.
  • Patient who is participating in another study that may affect this one.
  • ASPECTS score less than or equal to 6 on baseline CT.
  • Evidence of significant hemorrhage or mass effect with midline shift on baseline CT.
  • Patients with occlusions in multiple vascular territories.
  • Evidence of intracranial tumor (except for small meningiomas)

Study details
    Stroke
    Thrombectomy
    Arterial Occlusive Diseases

NCT05930145

Fundación EPIC

10 July 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.